Skip to content

5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS630 · #122443 · 2023
Citation
Web of Science 21Scopus 21
FWCI (Scopus)
1.55
JCR IF
JCR 2022 5.8
ISSN
0378-5173

Authors

  1. Lee, JuhoFirst authorPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  2. Bae, JunhwanPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  3. Kwak, Dong MinPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  4. Kim, HyunwooPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  5. Kim, JihyunPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  6. SHWE PHYU HLAINGPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  7. Aruzhan SaparbayevaPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  8. Lee, Eun HeeKorea Univ, Coll Pharm, Sejong 30019, South Korea
  9. Yoon, InsooPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  10. Kim, MinsooPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  11. Moon, HyungryoungPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea
  12. Yoo, JinwookCorresponding authorPusan Natl Univ, Coll Pharm, Pusan 46241, South Korea

Abstract

5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for colorectal cancer (CRC) owing to its potent anticancer effects. However, severe systemic side effects and poor drug accumulation in the CRC tissues limit its efficacy. This study aimed to develop 5-FU crystal-incorporated, pH-responsive, and release-modulating poly(D,L- lactide-co-glycolide)/Eudragit FS hybrid microparticles (5FU-EPMPs) for the local CRC-targeted chemotherapy. Approximately 150 mu m 5FU-EPMPs were fabricated via the S/O/W emulsion solvent evaporation method, with 7.93 +/- 0.24% and 87.23 +/- 2.64% 5-FU loading and encapsulation efficiencies, respectively. Drug release profiles in a simulated pH environment of the gastrointestinal tract revealed that premature 5-FU release in the stomach and small intestine was prevented, thereby minimizing systemic 5-FU absorption. After reaching the colon, 5-FU was continuously released for >15 h, allowing long-term exposure of CRC tissues to sufficient 5-FU concentra-tions. Furthermore, in a CRC mouse model, the 5FU-EPMPs showed potent inhibition of tumor growth without signs of systemic toxicity. Thus, the 5FU-EPMPs represent a promising drug delivery system for local CRC -targeted chemotherapy.

Keywords

5-fluorouracilpH-responsiveRelease modulationColorectal cancerColon-targeted deliveryLocal chemotherapyMESOPOROUS SILICA NANOPARTICLESCOLON-CANCERDRUG-DELIVERYMURINE COLITISDESIGNMICROSPHERES

Identifiers

Scopus EID
2-s2.0-85143511611
WoS UID
000897037200003